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Summary
Vitamin K-dependent proteins require carboxylation of certain glutamates for their biological 
functions. The enzymes involved in the vitamin K-dependent carboxylation include: gamma-
glutamyl carboxylase (GGCX), vitamin K epoxide reductase (VKOR) and an as-yet-unidentified 
vitamin K reductase (VKR). Due to the hydrophobicity of vitamin K, these enzymes are likely to 
be integral membrane proteins that reside in the endoplasmic reticulum. Therefore, structure-
function studies on these enzymes have been challenging, and some of the results are notably 
controversial. Patients with naturally occurring mutations in these enzymes, who mainly exhibit 
bleeding disorders or are resistant to oral anticoagulant treatment, provide valuable information for 
the functional study of the vitamin K cycle enzymes. In this review, we discuss: (i) the discovery 
of the enzymatic activities and gene identifications of the vitamin K cycle enzymes; (ii) the 
identification of their functionally important regions and their active site residues; (iii) the 
membrane topology studies of GGCX and VKOR; and (iv) the controversial issues regarding the 
structure and function studies of these enzymes, particularly, the membrane topology, the role of 
the conserved cysteines and the mechanism of active site regeneration of VKOR. We also discuss 
the possibility that a paralogous protein of VKOR, VKOR-like 1 (VKORL1), is involved in the 
vitamin K cycle, and the importance of and possible approaches for identifying the unknown 
VKR. Overall, we describe the accomplishments and the remaining questions in regard to the 
structure and function studies of the enzymes in the vitamin K cycle.
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Introduction
Vitamin K-dependent carboxylation is an essential post-translational modification that 
converts specific glutamate residues to gamma-carboxyglutamate (Gla) residues in vitamin 
K-dependent proteins. It is required for the biological function of numerous vitamin K-
dependent proteins, including clotting factors (such as factor (F) II, FVII, FIX and FX) and 
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natural anticoagulants (such as protein C, protein S and protein Z). Carboxylation is 
catalyzed by the enzyme gamma-glutamyl carboxylase (GGCX), which utilizes a reduced 
form of vitamin K (KH2), carbon dioxide and oxygen as cofactors. Concomitant with each 
glutamate modification, KH2 is oxidized to vitamin K 2,3-epoxide (KO). KO is converted 
back to KH2 through a two-step reduction (first to vitamin K, then to KH2) using the 
enzymes vitamin K epoxide reductase (VKOR) and vitamin K reductase (VKR) in a 
pathway known as the vitamin K cycle (Fig. 1).
Vitamin K-dependent carboxylation was originally observed in clotting factors [1,2]. In all 
clotting factors, 10 to 12 Gla residues are located in a homologous amino-terminal region 
referred to as the Gla domain [3]. The multiple Gla residues in this domain adopt a calcium-
dependent conformation that promotes clotting factors binding to a membrane surface [4], 
such as damaged vascular endothelial cells or activated platelets, which allows the 
localization of clotting factors near the site of vascular injury to either promote or regulate 
clotting.
With the discovery of new Gla proteins, vitamin K-dependent carboxylation has been 
implicated in a number of biological functions beyond coagulation. Osteocalcin is a Gla 
protein produced by osteoblasts and is important for bone formation [5]. Recent studies 
suggest that osteocalcin also functions as a hormone affecting glucose metabolism in mice 
[6,7]; whether this is the case in humans still needs to be elucidated [8,9]. The second Gla 
protein found in bone is matrix Gla protein (MGP), which functions as a strong inhibitor of 
vascular calcification and connective tissue mineralization [10]. Defects of MGP 
carboxylation have been associated with cardiovascular diseases and pseudoxanthoma 
elasticum (PXE) syndrome [11,12]. In addition, MGP has been described as a critical 
regulator of endothelial cell function, regulating both physiological and tumor-related 
angiogenesis [13]. Other vitamin K-dependent proteins that are not involved in coagulation 
include Gas6 (growth arrest-specific protein 6), PRGPs (proline-rich Gla proteins) and 
TMGs (transmembrane Gla proteins). The metabolic significance of most of these non-
coagulation Gla proteins is still poorly understood. A better understanding of the structure-
function relationship of the enzymes in the vitamin K cycle will help us to better understand 
and control a variety of biological processes.
Structure-function studies of GGCX
GGCX protein purification and gene discovery
The enzymatic activity of GGCX was first discovered in the 1970s, in the post-
mitochondrial supernatant of hepatocytes [14]. Since then, a number of groups have 
attempted to purify this integral membrane protein using different approaches; these include 
salt precipitation, immuno-adsorption and propeptide-based affinity chromatography [15–
17]. Knowing that GGCX interacts with the precursor of clotting factors, mainly through an 
18-amino acid propeptide, Hubbard et al. [16] attached the propeptide of prothrombin to 
Sepharose and affinity-purified GGCX from bovine liver microsomes. They found that 
carboxylation activity in their purified GGCX was 10 000-fold more enriched as compared 
with the crude microsomes. However, the specific activity of their purified enzyme was still 
not significantly different to that in the previous partially purified GGCX [18]. A 59-residue 
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peptide containing the propeptide and Gla domain of FIX (FIXQ/S) was later shown to be an 
excellent affinity ligand for GGCX purification [19]. Using FIXQ/S as the ligand, GGCX 
was purified up to 90% purity from bovine liver and had an apparent molecular weight of 94 
kDa in reduced SDS-PAGE analysis.
With purified bovine GGCX, tryptic peptides were sequenced and used for the PCR 
amplification of nucleotide fragments in order to screen a bovine liver cDNA library. The 
longest bovine cDNA insert was used to identify the gene of GGCX from a human liver 
cDNA library [15]. The identified human GGCX cDNA contains an open reading frame of 
2274 nucleotides encoding 758 amino acids. The GGCX gene is located at chromosome 2 at 
position p12, spans about 13 kb, and contains 15 exons [20,21].
Functional regions and critical residues in GGCX
Since the purification of GGCX and the cloning of its gene, significant progress has been 
made in understanding how GGCX interacts with its substrates and achieves catalysis [22]. 
GGCX is a dual-function enzyme with multiple substrates. It recognizes its protein substrate 
through a relatively tight binding to the propeptide of vitamin K-dependent proteins, which 
tethers the substrate to the enzyme [23]. During the process of carboxylation, the γ-
hydrogen of the glutamates of the substrate is abstracted, followed by the addition of CO2 
[24]. Simultaneously, GGCX oxidizes KH2 to KO to provide the energy required for the 
carboxylation [25]. Therefore, the functional regions and critical residues in GGCX include 
a propeptide binding site, a glutamate binding site, a vitamin K binding site, a carboxylation 
active site, an epoxidation active site and, possibly, a CO2 binding site.
The binding of the propeptide to GGCX initiates a structural reorientation of GGCX by 
which the Gla domain of the substrate is positioned at the catalytic site of GGCX [26,27]. 
Because GGCX is an integral membrane protein with limited structural information, 
identification of its functional regions has been very challenging and confusing. Using 
peptide-based affinity labeling and site-directed mutagenesis analysis, the propeptide 
binding site and the carboxylation active site were located within the N-terminal of GGCX 
between residues 1 and 225 [28,29]. However, results from limited trypsin digestion and 
site-directed mutagenesis studies suggest that the propeptide binding site was located at the 
C-terminal of GGCX, between residues 495 and 513 [30,31]. Characterization of the 
naturally occurring W501S GGCX mutation suggests that the major effect of this mutation 
is to decrease the affinity of GGCX for the propeptide binding [32]. Recently, GGCX was 
incorporated as single molecules into nanodiscs, which provide a native-like membrane 
environment; the assembled GGCX complexes were structurally stable and catalytically 
active [26]. Hydrogen/deuterium exchange mass spectrometry was used to characterize 
specific regions of GGCX that exhibited structural rearrangements upon binding to 
propeptides. One of the most pronounced enhancements in the deuterium exchange was 
observed in peptides 491–507. Together, these results suggest that the propeptide binding 
region is located in the C-terminal of GGCX.
Identification of GGCX’s glutamate binding site came primarily from the characterization of 
naturally occurring GGCX mutations and their neighboring conserved residues. Patients 
with homozygous mutations of L394R in GGCX have a severe bleeding disorder due to 
Tie and Stafford Page 3
J Thromb Haemost. Author manuscript; available in PMC 2016 October 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
decreased biological activities of all clotting factors [33]. In vitro characterization of the 
purified enzyme shows that the Ki of the competitive inhibitor for the pentapeptide FLEEL 
carboxylation is 110-fold higher for L394R than that of the wild-type enzyme [34]. 
Mutations of L394 and of neighboring residues, Y395 and W399, resulted in defective 
glutamate binding and significantly decreased carboxylation efficiency [35]. These results 
suggest that glutamate recognition is the primary function of the highly conserved region 
between residues 393 and 404 in GGCX. This glutamate-binding region of GGCX has been 
confirmed further by the nanodisc-hydrogen/deuterium exchange mass spectrometry study 
[26].
Identifying GGCX’s catalytic residues for carboxylation and epoxidation has been less 
successful. Numerous studies have suggested that free cysteine residues in GGCX are 
important for both carboxylation and epoxidation reactions [36–38]. Based on these 
observations, Dowd et al. [39] used a chemical model to develop a ‘base strength 
amplification mechanism’ for vitamin K-dependent carboxylation. They proposed that two 
free cysteines were involved in GGCX’s active site. One cysteine served as a weak base to 
deprotonate KH2, forming a strong base to abstract the γ-hydrogen of the glutamate, and the 
other cysteine provided the binding site of CO2. Further support for this hypothesis was 
provided by Pudota et al. [40], who suggested that C99 and C450 are the two active site 
cysteines required for both carboxylation and epoxidation reactions. However, results from 
site-directed mutagenesis, chemical modification and peptide fingerprinting suggest that 
cysteine residues are not involved in GGCX catalysis. Furthermore, C99 and C450 form the 
only disulfide bond in GGCX, which is important for GGCX stability [41,42]. That GGCX’s 
catalytic residues are not cysteines has been further confirmed by Rishavy et al. [43], who 
suggest that the catalytic base, which deprotonates KH2, is not a cysteine but an activated 
amine.
According to the ‘base strength amplification mechanism’, a weak base in GGCX is required 
for the conversion of KH2 to a strong base [39]. A quantum chemical study suggests that the 
alkoxide of vitamin K is most likely the strong base that abstracts a proton from the γ-
carbon of glutamates [44,45]. After the initial step (the removal of a proton from KH2), the 
energetics of the reaction are thermodynamically favorable. Cysteines have been excluded as 
GGCX’s weak base [41–43]; the candidate base residues were searched using sequence 
alignment of the Leptospira GGCX homolog with mammalian orthologs [46]. Three 
conserved histidines and one conserved lysine were identified. Mutating these candidate 
residues to alanine showed that only the K218A mutant was completely inactive for both the 
carboxylation and the epoxidation reactions. In addition, the activity of the K218A mutant 
could be rescued with small amines. Based on this study, the authors concluded that K218 
(together with K217) serves as the weak base to deprotonate KH2 and initiate the 
carboxylation reaction.
Membrane topology of GGCX
To better understand the structure and function relationships of integral membrane proteins, 
it is necessary to know their membrane topologies, especially when their three-dimensional 
structure is unavailable. To determine the membrane topology of GGCX, Tie et al. [47] used 
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in vitro translation/cotranslocation, combined with an N-linked glycosylation reporter tag, to 
map the topological orientation of the predicted transmembrane domain (TMD) in the 
GGCX sequence. In addition, they determined the orientations of the amino and carboxyl 
termini of full-length GGCX by expressing the tagged proteins in HEK293 cells. Results 
from this study suggest that GGCX spans the endoplasmic reticulum (ER) membrane five 
times, with its amino terminus located in the cytoplasm and its carboxyl terminus located in 
the ER lumen (Fig. 2). This topology model places the identified propeptide binding site, the 
glutamate binding site and the vitamin K deprotonate active site in the ER lumen, which is 
where vitamin K-dependent carboxylation occurs.
This topology, however, has been called into question by placing a vitamin K-dependent 
protein binding sequence (VKS, residues 343–355) in the cytoplasm [48,49]. To clarify this 
issue, microsomes from insect cells expressing GGCX were treated with proteinase K, and 
the luminal protected fragment was purified [41]. The N-terminal sequence of the purified 
fragment corresponds to the sequence of GGCX, starting from residue 352, confirming the 
cytoplasmic location of the VKS region. In addition, results from the functional expression 
of a two-chain GGCX suggest that the fifth TMD in the proposed topology model is the last 
and only TMD in the C-terminal peptide of the two-chain GGCX [50], a finding that further 
supports the proposed topology model of GGCX.
GGCX genotype and the clinical phenotype
Since the identification of the GGCX gene, over 30 naturally occurring GGCX mutations 
have been discovered in patients with vitamin K-related disorders [51]. Characterization of 
some of these mutations provides invaluable information regarding the function of GGCX. 
Defects of vitamin K-dependent carboxylation have long been known to cause bleeding 
disorders, referred to as vitamin K-dependent coagulation factors deficiency (VKCFD) [52]. 
Recently, GGCX mutations have also been linked to non-bleeding clinical phenotypes, 
mainly the PXE-like syndrome [53]. The PXE-like syndrome is characterized by aberrant 
mineralization of soft connective tissue resulting in fragmentation of elastic fibers, involving 
primarily the skin, eyes and cardiovascular system [54]. GGCX mutations in PXE-like 
patients resulted in a lower level of carboxylated MGP – a strong inhibitor of vascular 
calcification and connective tissue mineralization. Some PXE-like patients have comorbid 
VKCFD syndrome [53], while others have normal blood coagulation [55]. It is not clear why 
some GGCX mutations result in bleeding disorders while others cause non-bleeding 
syndromes. This is mainly because our current knowledge of GGCX’s function was 
obtained from in vitro experimentation under artificial conditions, which has limited 
usefulness in understanding the clinical consequences of these mutations. To better address 
this issue, a GGCX-deficient mouse strain was generated by gene targeting [56]. However, 
due to embryonic lethality, all homozygous GGCX-deficient mice succumbed to massive 
intra-abdominal hemorrhages shortly after birth. While liver-specific GGCX-deficient mice 
have been created to again attempt to examine GGCX function in vivo [57], it appears that 
manipulating GGCX variants and GGCX substrates in mice is impracticable. Recently, 
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)-Cas9 was used to 
create a GGCX-deficient cell line that contains vitamin K-dependent reporter proteins, 
Tie and Stafford Page 5
J Thromb Haemost. Author manuscript; available in PMC 2016 October 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
which appears to be a very useful tool for studying the functional consequences of GGCX 
mutations in their native milieu [58].
Structure-function studies of VKOR
VKOR protein purification and gene discovery
Since the discovery of the enzymatic activity of VKOR in 1970 [59], numerous attempts to 
purify VKOR from hepatic microsomes have been unsuccessful [60–63]. Purification of 
VKOR is exceptionally difficult because it is rendered inactive by any detergent that 
achieves its solubilization. Due to the loss of activity that accompanied purification, it was 
postulated that VKOR was a multi-enzyme complex.
The first partial purification of VKOR was reported in 1985 [63]. Sodium cholate-
solubilized rat hepatic microsomes were separated by a discontinuous sucrose gradient to 
isolate a 200S microsomal sub-fraction that contained VKOR activity. However, attempts to 
further purify VKOR from the 200S fraction resulted in loss of enzymatic activity. A ~17 
kDa warfarin-sensitive protein was identified by chemical modification of the free cysteines 
using radioactive N -[3H]ethylmaleimide ([3H]NEM). Both KO and warfarin can effectively 
block the incorporation of [3H]NEM into the reduced protein. Therefore, it has been 
suggested that the [3H]NEM-labeled component is a single polypeptide containing one 
disulfide bond that exhibits VKOR activity. As VKOR was generally thought to be a multi-
enzyme complex, the authors concluded that it was unlikely that a single peptide of 
relatively low molecular weight could catalyze these complex reactions [63]. In fact, the 
results of Lee et al. [64] agree well with the fact that VKOR is an 18 kDa enzyme that 
employs a CXXC redox center as its active site.
Still mistakenly assuming that VKOR was a multi-enzyme complex, VKOR purification 
then focused on searching for the potential component(s). Cain et al. [62] subjected CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate)-solubilized rat liver 
microsomes to a gel-filtration column. Enzymatic activity was lost, but some activity could 
be regained by combining the flow-through and the retained fractions. The flow-through was 
further separated by ion-exchange chromatography; the unbound fraction also restored 
VKOR activity. Characterization of the unbound proteins suggested that microsomal epoxide 
hydrolase (mEH), an integral membrane protein, was the second component of the assumed 
VKOR complex [61,62]. However, it was later shown that a mouse knockout of mEH had no 
defects in vitamin K metabolism [65], which indicated that mEH was not involved in KO 
reduction. Therefore, it is very unlikely that VKOR is actually a multi-enzyme complex.
Traditional biochemical approaches to protein identification did not contribute to VKOR 
identification, even after several decades of efforts. It was not until 2004 that the gene 
encoding VKOR was identified independently by two laboratories using alternative 
approaches: siRNA functional screening and interspecies genetic linkage analysis [66,67]. 
The putative VKOR gene was found to encode for a 163-amino acid protein and was 
confirmed by overexpression in insect cells and HEK293 cells. Recombinant VKOR has 
been purified from insect cells [64], and this purified single-peptide enzyme can accomplish 
both the conversion of KO to vitamin K and vitamin K to KH2 [64].
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Functional regions and critical residues in VKOR
The cloning of the VKOR gene made it possible to study VKOR functions at the molecular 
level. Shortly after the identification of the VKOR gene, a protein sequence alignment of 
widely divergent species showed that four cysteines (C43, C51, C132 and C135 of human 
VKOR) are absolutely conserved; these cysteines are proposed to be VKOR’s active site 
residues [68] (Fig. 3). The C132XXC135 motif was hypothesized to perform the nucleophilic 
attack on vitamin K epoxide, as proposed by a chemical model study [69]. This hypothesis 
was confirmed by mutagenesis studies showing that mutating either of the cysteines renders 
VKOR inactive [70–72].
While there is no doubt that the CXXC motif is VKOR’s active site, the role of the other two 
conserved cysteines (C43 and C51, the loop cysteines) remains controversial. Based on 
studies of bacterial VKOR homologues (VKORHs), the loop cysteines of human VKOR 
were proposed to shuttle electrons to the active site cysteines [73,74]. It is clear that the loop 
cysteines in bacterial VKORHs accept electrons from their Trx-like domain or from DsbA; 
these electrons are then transferred to the active site cysteines [75]. Mutating either of the 
loop cysteines blocks the electron transfer pathway and renders the enzyme inactive. 
However, the mechanism in human VKOR appears to be different. Although the C43S 
mutation significantly decreased VKOR activity, VKOR molecules with C51 mutated to 
serine or with both C43 and C51 mutated to serine retained almost full activity [70,72]. This 
suggests that the loop cysteines are not required for VKOR activity. A caveat to this 
conclusion is that these studies used dithiothreitol as a reductant to reduce the active site 
disulfide in vitro, which may bypass the function of the loop cysteines.
Recently, a cell-based assay was established for the functional study of vitamin K cycle 
enzymes in mammalian cells using a chimeric vitamin K-dependent reporter protein [76]. 
The reporter protein in this assay is protein C (PC) with its Gla domain replaced by that of 
FIX (FIXgla). The rationale for using FIXgla-PC as the reporter protein is that the 
uncarboxylated reporter protein should be selectively degraded by the cells [77] to decrease 
the background; FIXgla enables the ready detection of the carboxylated reporter protein by a 
conformational specific monoclonal antibody that recognizes only carboxylated FIXgla. For 
functional studies of VKOR, transcription activator-like effector nucleases (TALENs)-
mediated genome editing was used to knockout the endogenous VKOR and VKORL1 genes 
in the reporter cells [78]. A VKOR molecule with both C43 and C51 mutated to alanine 
retains ~90% activity in cell-based assays compared with the wild-type enzyme. 
Additionally, the entire loop between the two cysteines (including C43 and C51) can be 
deleted with only a minor effect on VKOR’s activity. These results strongly suggest that 
transfer of electrons from the loop cysteines to the active site cysteines cannot be the major 
mechanism in human VKOR.
VKOR is the target of warfarin – the most widely used oral anticoagulant. Naturally 
occurring VKOR mutations have been detected, and these mutations result in warfarin 
resistance in rats, mice and humans. As these mutations are widely dispersed throughout the 
VKOR sequence, and not all the mutations are resistant to warfarin inhibition in a cell-based 
assay [78], it seems unlikely that all of these residues are involved in warfarin binding. The 
most frequent mutation residue, Y139, together with its neighboring residues (TY139A), has 
Tie and Stafford Page 7
J Thromb Haemost. Author manuscript; available in PMC 2016 October 21.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
been proposed to be part of the warfarin-binding site [79]. The Y139F VKOR mutant is 
resistant to warfarin inhibition; because the only difference between tyrosine and 
phenylalanine is the hydroxyl group, this hydroxyl group is therefore proposed to play an 
essential role in warfarin binding [72]. Interestingly, in a functional study of the 
consequences of warfarin-resistant VKOR mutants on the recycling of vitamin K, Matagrin 
et al. [80] reported that all functional VKOR mutants at residue Y139 produce 3-
hydroxyvitamin K, suggesting that the hydroxyl group of Y139 is involved in the catalytic 
mechanism corresponding to the dehydration of KO. These results together suggest that the 
TYA and CXXC motifs form a binding pocket for both the substrate (KO) and inhibitor 
(warfarin) binding.
In addition to affecting warfarin sensitivity, one naturally occurring mutation in VKOR 
(R98W) has been associated with VKCFD [66]. Characterization of the R98W mutant 
suggests that this mutation disrupts a diarginine ER retention motif, resulting in 
mislocalization of the mutated protein to the ER, and exits the ER membrane by cellular 
quality control systems [81].
Membrane topology of VKOR
The membrane topology of VKOR has been a major controversy in the community of 
VKOR researchers. Both three- and four-TMD topology models have been proposed for 
VKOR; these are based on biochemical approaches [82,83] and on the crystal structure of a 
bacterial (Synechococcus) VKORH (Syn-VKORH) [74]. Although the membrane 
orientations of the last two TMDs of VKOR are not in doubt, the orientation of the first 
TMD is a source of contention. The three-TMD model suggests a Nout/Cin orientation for 
TMD1; a Nin/Cout orientation is suggested by the four-TMD model. One of the main factors 
that affects the orientation of the TMD is the distribution of the charged residues flanking 
the hydrophobic transmembrane segment, called the ‘positive inside rule,’ which applies to 
both bacterial and mammalian membrane proteins [84,85]. As human VKOR and Syn-
VKORH have different charged-residue distributions flanking the first TMD, the ‘positive 
inside rule’ predicts a three-TMD model for human VKOR and a four-TMD model for Syn-
VKORH. Additionally, human VKOR and Syn-VKORH only share ~20% sequence identity, 
so deducting the membrane topology of human VKOR from Syn-VKORH may not be 
appropriate. Furthermore, the three-TMD model is based on an examination of the potential 
of each predicted TMD of human VKOR to function as an authentic stop-transfer sequence 
and the detection of the termini locations of full-length VKOR in both intact microsomes 
and in live cells in situ [82,83]. This makes it more likely that human VKOR is a three-TMD 
protein (Fig. 4A).
In the three-TMD model, the CXXC active site of VKOR is located within the last TMD, 
close to the ER lumen. The hydrophobic environment of the CXXC redox center is 
consistent with the hydrophobicity of the vitamin K substrate. In addition, four of the six 
tryptophan residues in VKOR are located in the membrane’s bilayer interface. Tryptophan 
residues have been shown to exhibit a strong tendency to remain within the interfacial 
region, serving as anchoring residues that fix the transmembrane helix within the lipid 
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bilayer [86]. Therefore, the positively charged residues and the tryptophan residues in 
VKOR both seem to lock VKOR into a three-TMD configuration.
Clarifying the topological structure of VKOR is important because the two existing topology 
models place the functionally disputed conserved loop cysteines on different sides of the ER 
membrane. The three-TMD model places the conserved loop cysteines in the cytoplasm, the 
opposite side of the ER membrane from the CXXC active site. It has been argued that the 
three-TMD model is unlikely because the loop cysteines transfer electrons to the active site. 
It is worth noting that VKOR can be changed from a three-TMD molecule to a fully active 
four-TMD molecule by mutating the positively charged residues flanking the first TMD 
[82]. However, even when the loop cysteines are located on the same side of the ER 
membrane as the active site cysteines, they do not appear to be involved in electron transfer 
[82]. Interestingly, Mycobacterium tuberculosis VKORH (Mt-VKOR) has four TMDs in its 
VKOR domain and has its loop cysteines located on the same side of the membrane as the 
active site cysteines. These loop cysteines are clearly required for Mt-VKORH’s activity in 
E. coli [87] but are not essential for vitamin K reduction in mammalian cells [88]. Results 
from these studies suggest that the conserved loop cysteines in VKOR are not involved in 
active site regeneration, and that VKOR’s active site is directly reduced by an as-yet-
unknown physiological reductant.
Further support for the three-TMD topology model of VKOR comes from a molecular 
dynamics simulation of VKOR in a palmitoyl-oleoyl-phosphatidylethanolamine lipid bilayer 
[89]. This study shows that the three-TMD topology model of VKOR is more stable than the 
four-TMD model, as the hydrophobic interactions between leucine residues in different 
transmembrane helices only occur in the three-TMD model (Fig. 5A). Additionally, in the 
four-TMD model, residue Y139 of the warfarin-binding motif faces to the outside of the 
core of the TMDs, whereas in the three-TMD model, Y139 interacts with Y25 through a 
H2O molecule to form a substrate/warfarin binding pocket (Fig. 5B).
Structure-function study of VKORL1
During the identification of VKOR, homologous searches with VKOR detected a paralogous 
protein called VKOR-like 1 (VKORL1) [66]. VKORL1 appears to have a different 
membrane topology (Fig. 4B) and a different mechanism for its active site regeneration as 
compared with VKOR [90]. Although the structure-function relationships of VKOR have 
been extensively studied, the functional study of VKORL1 has not been reported until 
recently [90–93].
Westhofen et al. [93] expressed VKORL1 in HEK293 cells, then examined VKORL1’s 
ability to reduce KO and vitamin K from crude cell membranes. This study showed that 
VKORL1 reduces KO 18 054-fold slower than VKOR. Based on these results, the authors 
hypothesized that the primary physiological function of VKORL1 is to reduce vitamin K to 
KH2. As KH2 has been reported to be an effective antioxidant, helping to prevent cell death 
caused by oxidative stress, these authors further concluded that VKORL1 was responsible 
for driving vitamin K-mediated intracellular antioxidation pathways that were critical to cell 
survival. It should be noted, however, that this conclusion is based on comparing the specific 
enzymatic activity of VKORL1 in crude cell membranes (total proteins) in the presence of 
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detergent with that of purified VKOR reconstituted in intact membranes [64]. As cell-based 
studies show that VKORL1 has a substantial role in reducing KO to support vitamin K-
dependent carboxylation, and HEK293 cells with both VKOR and VKORL1 ablated grow 
and function normally [78,90], it is premature to conclude that the primary physiological 
function of VKORL1 is to prevent oxidative stress in cells.
A recent study suggests that VKORL1 might rescue VKOR’s activity in extrahepatic tissues 
during anticoagulation therapy [92]. In this study, VKORL1 and VKOR were expressed in 
Pichia pastoris and their susceptibility to vitamin K antagonists (VKAs) was compared using 
a DTT-driven microsomal activity assay. Results from this study show that the catalytic 
efficiency of VKORL1 in reducing KO is two-fold higher than that of VKOR. Compared 
with VKOR, VKORL1 is ~50-fold more resistant to VKA inhibition. VKOR’s and 
VKORL1’s mRNA level and KO reductase activity were also compared in mouse and rat 
tissues. In liver, the mRNA level of VKORL1 is ~10-fold lower than that of VKOR, while in 
extrahepatic tissues the mRNA level of VKORL1 is systematically higher than that of 
VKOR. Results from activity assays of rat tissues suggest that VKOR contributes more than 
90% of the KO reductase activity in liver, while VKORL1 contributes ~55% of the KO 
reductase activity in testis and ~22% in lung. Based on these results, the authors suggest that 
VKORL1 supports vitamin K-dependent carboxylation mainly in extrahepatic tissues and 
rescues VKOR’s activity during anticoagulation therapy.
Although VKORL1 can efficiently reduce KO to support vitamin K-dependent 
carboxylation in the DTT-driven and cell-based assays [78,90,92], it appears unlikely that 
VKORL1 plays a key role in the vitamin K cycle under physiological conditions. If so, the 
murine knockout of VKOR would be viable [94] and no significant decrease of KO 
reductase activity in the VKOR knockout cells would have been observed [78].
Functional studies of VKR
To date, we know very little about the enzymes that reduce vitamin K, but there are several 
lines of evidence that demonstrate VKR’s importance. Most notably, patients that are 
overdosed with warfarin can be rescued by large doses of vitamin K through the action of a 
warfarin-resistant enzyme that reduces vitamin K, designated as the ‘antidotal enzyme’. The 
antidotal effect of vitamin K was first discovered in 1966 [95] and was recently 
demonstrated in the VKOR-knockout mouse [94] and in a cell-based vitamin K cycle 
enzyme study [76]. However, despite decades of effort [96–98], the identity of VKR is still 
unknown.
It has been proposed that vitamin K is reduced to KH2 via two pathways [97]: a warfarin-
sensitive pathway (accomplished by VKOR) and a warfarin-resistant pathway (catalyzed by 
a NAD(P)H-dependent antidotal enzyme). As VKOR is capable of reducing vitamin K to 
KH2 [64, 70, 99], it has been proposed that VKOR could form a dimer with one molecule 
reducing KO to vitamin K and the other molecule reducing vitamin K to KH2 [99]. 
However, studies using the purified enzyme suggest that VKOR reduces KO to vitamin K 
~50-fold faster than it reduces vitamin K to KH2 [64]. When VKOR is inactivated by 
warfarin or knocked out by gene targeting in HEK293 cells, those cells can still efficiently 
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reduce vitamin K to support vitamin K-dependent carboxylation [76,78]. Additionally, 
VKOR-deficient mice died due to extensive intracerebral hemorrhage; however, this lethal 
phenotype could be rescued by the oral administration of vitamin K [94]. Furthermore, 
VKOR was unable to convert KO directly to KH2 to support vitamin K-dependent 
carboxylation in a cell-based assay [76]. Therefore, it is unlikely that VKOR is the major 
physiological contributor to vitamin K reduction.
NQO1 (NAD(P)H quinone oxidoreductase 1) has long been known as the warfarin-resistant 
antidotal enzyme for vitamin K reduction [98]. Rat liver microsomes depleted of NQO1 
displayed reduced vitamin K-dependent carboxylation activity, and this activity could be 
restored by adding purified NQO1 [97]. However, dicoumarol, a strong inhibitor of NQO1, 
was unable to inhibit vitamin K reduction in HEK293 cells [76], and NQO1-deficient mice 
survived at the same frequency as wild-type mice when poisoned with warfarin [96]. In 
addition, an enzyme kinetic study of membrane fractions from mouse liver microsomes 
shows the existence of NAD(P)H-dependent VKR activity in both wild-type and NQO1-
deficient mice [96]. These results suggest that NQO1 is not the antidotal enzyme for 
reducing vitamin K to KH2 under physiological conditions.
VKR, like GGCX and VKOR, is likely to be an integral membrane protein residing in the 
ER [96]. Traditional biochemical approaches to protein identification are often unsuccessful 
for membrane protein identification, as illustrated by the history of efforts to identify 
VKOR. The identification of VKOR spanned several decades and was ultimately achieved, 
not by biochemical approaches, but by alternative approaches employing interspecies 
genetic linkage analysis [66] and siRNA functional screening [67]. We believe that a similar 
non-traditional approach to protein identification may be the key to identifying VKR. One 
promising avenue is the recently developed genome-scale CRISPR-Cas9 knockout library 
screening [100]. Detailed insights into the characteristics of warfarin-resistant and warfarin-
sensitive VKRs will not only extend our understanding of the mechanism of vitamin K 
reduction, but will also help us to develop new ways of regulating coagulation and treating 
thrombosis.
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Fig. 1. 
Vitamin K cycle. During vitamin K-dependent carboxylation, glutamate (Glu) is converted 
to gamma-carboxyglutamte (Gla) by gamma-glutamyl carboxylase (GGCX) using a reduced 
form of vitamin K (KH2), carbon dioxide, and oxygen as cofactors. KH2 is oxidized to 
vitamin K epoxide (KO). KO is reduced to vitamin K by vitamin K epoxide reductase 
(VKOR). The reduction of vitamin K to KH2 is carried out by VKOR and an as-yet-
unidentified VKR.
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Fig. 2. 
Proposed membrane topology of gamma-glutamyl carboxylase (GGCX). GGCX spans the 
endoplasmic reticulum (ER) membrane five times with its N-terminus located in the 
cytoplasm and C-terminus located in ER lumen. The glutamate binding site is shown as 
orange filled circles; the propeptide binding site is shown as blue filled circles; the proposed 
vitamin K deprotonation residues are shown as red filled circles; and the disulfide linked 
cysteines are shown as yellow filled circles.
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Fig. 3. 
Multiple sequence alignment of vitamin K epoxide reductase (VKOR) near the conserved 
cysteine residues. The amino acid sequences of VKOR from widely divergent species were 
aligned by CLUSTAL W. Completely conserved cysteine residues are indicated by numbers 
according to the position of amino acid residues in the human VKOR sequence.
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Fig. 4. 
Proposed membrane topology of vitamin K epoxide reductase (VKOR) and VKORL1. (A) 
A three-transmembrane domain (TMD) topology model of VKOR is illustrated. The N-
terminus of VKOR is located in the endoplasmic reticulum (ER) lumen and the C-terminus 
located in the cytoplasm. The positively charged residues flanking TMD1 are shown as 
purple filled circles; the membrane interfacial tryptophans are shown as yellow filled circles; 
and conserved active site cysteines and loop cysteines are shown as red filled circles. (B) A 
four-TMD topology model of VKORL1 is illustrated. Both the N-terminus and C-terminus 
of VKORL1 are located in the cytoplasm. Conserved active site cysteines and loop cysteines 
are shown as red filled circles.
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Fig. 5. 
Molecular dynamics simulations of vitamin K epoxide reductase (VKOR) as a three-
transmembrane domain (TMD) molecule. (A) Five hydrophobic interactions between 
leucine and/or isoleucine residue pairs within TMDs stabilize the three-TMD topology 
model of VKOR. (B) The proposed warfarin binding residue Y139 (in the TYA motif) is 
stabilized by interaction with a tyrosine in TMD1 (Y25) via a water network.
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